The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has announced its financial results from the last quarter, ending on September 30, 2015.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has announced its financial results from the last quarter, ending on September 30, 2015.
According to the press release:
“The Synergy team continues to successfully execute on our key pipeline and corporate objectives,” said Gary S. Jacob, Chairman and CEO of Synergy. “Our strong year-to-date performance has resulted in a significant increase in value for our shareholders, enabling us to strengthen our balance sheet and financial position by reducing our debt by over 20%. We anticipate the next year will be marked by a number of value-enhancing opportunities, including our first planned NDA filing with plecanatide for CIC this coming January, pivotal results from our two ongoing phase 3 IBS-C trials, and a second NDA filing with plecanatide for IBS-C, all while building an agile commercial organization as we prepare for a potential U.S. launch with plecanatide in early 2017. The team remains focused on flawless execution across all areas of our business and we look forward to a very exciting 2016.”
Click here to read the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.